iRhythm Acquires VitalConnect for $287.5M to Expand Cardiac Monitoring Platform — iRhythm Holdings, Inc.

Event summary

iRhythm to acquire VitalConnect for $287.5M, consisting of $237.5M in cash and $50M in iRhythm common stock.
Transaction expected to close by the end of 2026, subject to regulatory approvals.
VitalConnect's platform adds multi-vitals monitoring capabilities and expands iRhythm's addressable market across ambulatory, inpatient, and hospital-to-home care settings.
iRhythm aims to enhance its revenue growth rate beginning in 2027 while maintaining a 15% adjusted EBITDA margin target for the same year.

The big picture

This acquisition positions iRhythm to broaden its cardiac monitoring capabilities beyond ambulatory settings into hospitals and remote care. The deal reflects a trend in digital health towards consolidating technologies that enable continuous patient monitoring across diverse care environments. With a $287.5M price tag, the transaction underscores the strategic value of integrating multi-vitals monitoring into existing cardiac diagnostics platforms.

What we're watching

Integration Challenges: How iRhythm will integrate VitalConnect's technology and workforce into its existing operations without disrupting current services.
Revenue Acceleration: Whether the acquisition will drive meaningful revenue growth starting in 2027 as projected, given the competitive landscape.
Market Expansion: The pace at which iRhythm can leverage VitalConnect's platform to penetrate new markets and care settings, particularly inpatient monitoring and hospital-to-home care.